House Bill Seeks to Abolish PTAB & AIA
Contributed by Ropes & Gray. Originally published on Patexia; republished here as part of the LexDana archive.
Political Theater & Patent Reform
The Stronger Patent Act has failed to gain traction for several years now. The Bill is deemed to one-sided, proposing legislative changes that would effectively kill AIA trial proceedings. Strangely, a new bill was introduced last week that goes even further.
The so-called Restoring America’s Leadership in Innovation Act (here) proposes to disband the Patent Trial & Appeal Board (PTAB) and with it, AIA trial proceedings. The new bill also seeks to convert the U.S. system back to a first-to-invent system. The Bill is sponsored by Rep. Thomas Massie (R-Ky.) and co-sponsored by Reps. Marcy Kaptur (D-Ohio) and Dana Rohrabacher (R-Calif.). Some may recall Reps. Rohrabacher and Kaptur as being opponents of the post-grant mechanisms of the AIA.
While perhaps heartening to critics of the PTAB, the latest bill is little more than political theater. With mid-term elections on the way, and a Supreme Court nomination battle, attempts at patent reform will have to wait until 2019 – assuming a balanced bill ever emerges.
Scot t A. McKeown is an author of the Patents Post Grant.
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…